Eli Lilly Shifting Direction of Alzheimer’s Research

Eli Lilly is acquiring a diagnostic tool from Siemens, in efforts to shift the direction of research in Alzheimer’s, which has yielded little results in treating the amyloid plaque build-up in the brain, to fibrous bundles of protein tau.

Advertisements